Eli Lilly reported less knee pain with retatrutide over 68 weeks and better results from Taltz plus Zepbound than Taltz alone. These findings support its drug research, though no sales or approval change is reported.
The findings give Lilly evidence that its medicines may help people beyond weight management alone. The story reports trial results, not new sales or an approval, so any business benefit still depends on further progress.
Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLY